Találati lista | Tudóstér

001-es BibID:	BIBFORM028489
Első szerző:	Lakatos Péter (Semmelweis Egyetem)
Cím:	DLG5 R30Q is not associated with IBD in Hungarian IBD patients but predicts clinical response to steroids in Crohn's disease / Lakatos P. L., Fischer S., Claes K., Kovacs A., Molnar T., Altorjay I., Demeter P., Tulassay Z., Palatka K., Papp M., Rutgeerts P., Szalay F., Papp J., Vermeire S., Lakatos L., The Hungarian IBD Study Group
Dátum:	2006
ISSN:	1078-0998
Megjegyzések:	Recent data suggest that haplotypic variants of the DLG5 gene on 10q23 are associated with susceptibility to inflammatory bowel disease (IBD) in Germany. In view of the geographical differences in frequency of genetic markers and the absence of data in Central European patients, our aim was to determine the DLG5 R30Q variant in Hungarian IBD patients. MATERIALS AND METHODS: We investigated 773 unrelated IBD patients (age 38.1 +/- 10.3 years; duration, 8.8 +/- 7.5 years; Crohn's disease [CD]: 639; male/female, 309/330; duration, 8.4 +/- 7.1 years; ulcerative colitis [UC]: 134; male/female, 63/71; duration, 10.6 +/- 8.9 years) and 150 healthy subjects. DLG5 R30Q and TLR4 D299G variants were tested by polymerase chain reaction/restriction fragment length polymorphism. DNA was screened for NOD2/CARD15 mutations by denaturing high-performance liquid chromatography. Detailed clinical phenotype was determined by reviewing the medical charts. RESULTS: The frequency of the R30Q variant allele was not significantly different in IBD (22.0%), CD (20.8%), and UC (27.6%) patients compared with healthy control subjects (28.0%). In CD, the 113A variant allele was associated with steroid resistance (16.3% vs noncarriers, 7.6%; odds ratio [OR], 2.4; 95% CI 1.3-4.5; P = 0.013). In a logistic regression model carriage of DLG5 R30Q, perianal involvement and frequent relapses were independently associated with steroid resistance. No phenotype-genotype associations were found in UC patients, although a trend toward more extensive disease was observed in carriers of the variant allele (OR = 2.1; 95% CI 0.95-4.4; P = 0.07). CONCLUSIONS: The present data strongly contrast previous data from Germany. DLG5 113A is not associated with disease susceptibility, but there was a tendency for this allele to confer resistance to steroids. Further studies are required to evaluate the significance of DLG5 in other populations from geographically diverse regions.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban egyetemen (Magyarországon) készült közlemény
Megjelenés:	Inflammatory Bowel Diseases. - 12 : 5 (2006), p. 362-368. -
További szerzők:	Fischer Simon Claes, Karolien Kovács Ágota Molnár Tamás (orvos Szeged) Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Demeter Pál Tulassay Zsolt (1944-) (belgyógyász, gasztroenterológus) Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Papp Mária (1975-) (belgyógyász, gasztroenterológus) Rutgeerts, Paul Szalay Ferenc (belgyógyász) Papp János (Budapest) Vermeire, Séverine Lakatos László (Veszprém) The Hungarian IBD Study Group
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM121591
035-os BibID:	(scopus)85191105736 (wos)001103520000001
Első szerző:	Vermeire, Séverine
Cím:	Early Versus Late Use of Vedolizumab in Ulcerative Colitis : Clinical, Endoscopic, and Histological Outcomes / Vermeire Séverine, Hanzel Jurij, Löwenberg Mark, Ferrante Marc, Bossuyt Peter, Hoentjen Frank, Franchimont Denis, Palatka Károly, Peeters Harald, Mookhoek Aart, de Hertogh Gert, Molnár Tamás, van Moerkercke Wouter, Lobatón Triana, Clasquin Esmé, Hulshoff Melanie S., Baert Filip, D'Haens Geert, LOVE-UC study group
Dátum:	2024
ISSN:	1873-9946
Megjegyzések:	Background and Aims: We explored the potential for differential efficacy of vedolizumab between early and late ulcerative colitis [UC] with evaluation of clinical, endoscopic, and histological endpoints. Methods: This was a multicentre, multinational, open-label study in patients with moderately-to-severely active UC, defining early UC by a disease duration <4 years and bio-naïve and late UC by a disease duration > 4 years and additional exposure to tumour necrosis factor antagonists. Patients received standard treatment with intravenous vedolizumab for 52 weeks [300 mg Weeks 0, 2, 6, every 8 weeks thereafter without escalation]. The primary endpoint was corticosteroid-free clinical remission with endoscopic improvement [total Mayo score ?2 with no subscore >1] at both Weeks 26 and 52. Results: A total of 121 patients were included: in the "early" group, 25/59 [42.4%] achieved the primary endpoint versus 19/62 [30.6%] in the "late" group [p = 0.18]. There were no significant differences between the two groups in endoscopic improvement [Week 26: "early" 32/59 [54.2%] versus "late" 29/62 [46.8%]; p = 0.412; Week 52: 27/59 [45.8%] versus 25/62 [40.3%]; p = 0.546] or in histological remission [Robarts Histopathology Index <3 without neutrophils in the epithelium and lamina propria] [Week 26: 24/59 [40.7%] versus 21/62 [33.9%]; p = 0.439; Week 52: 22/59 [37.3%] versus 22/62 [35.5%]; p = 0.837]. Conclusions: No significant differences in clinical, endoscopic, and histological outcomes were observed between "early" and "late" disease.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk anti-integrin biologic inflammatory bowel disease LOVE-UC Trial
Megjelenés:	Journal of Crohns & Colitis. - 18 : 4 (2024), p. 540-547. -
További szerzők:	Hanzel, Jurij Löwenberg, Mark Ferrante, Marco Bossuyt, Peter Hoentjen, Frank Franchimont, Denis Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Peeters, Harald Mookhoek, Aart de Hertogh, Gert Molnár Tamás (orvos Szeged) van Moerkercke, Wouter Lobatón, Triana Clasquin, Esmé Hulshoff, Melanie S. Baert, Filip D'Haens, Geert LOVE-UC study group
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: